Home › Funds › ArchPoint Investors › RGNX
ArchPoint Investors position in RGNX
REGENXBIO INC · Health Care
ArchPoint Investors reported holding 216,803 shares of RGNX (REGENXBIO INC) in its Q3 2026 13F filing — a position valued at US$1.6M, representing 0.35% of its reported portfolio and ranking #47 among its reported holdings. ArchPoint Investors has disclosed RGNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ArchPoint Investors's RGNX position evolved
ArchPoint Investors first disclosed a stake in RGNX in Q3 2023 at 224,278 shares (US$3.7M). The position peaked in Q1 2024 at 224,278 shares, worth US$4.7M. Across 13 filings, ArchPoint Investors increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 216,803 shares valued at US$1.6M — a reduction of -5,475 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 224.28K | $3.69M | New |
| Q4 2023 | 224.28K | $4.03M | Hold |
| Q1 2024 | 224.28K | $4.73M | Hold |
| Q2 2024 | 224.28K | $2.62M | Hold |
| Q3 2024 | 224.28K | $2.35M | Hold |
| Q4 2024 | 221.53K | $1.71M | Reduce |
| Q1 2025 | 221.53K | $1.58M | Hold |
| Q2 2025 | 220.53K | $1.81M | Hold |
| Q3 2025 | 223.53K | $2.16M | Add |
| Q4 2025 | 222.28K | $3.20M | Reduce |
| Q1 2026 | 222.28K | $1.86M | Hold |
| Q2 2026 | 222.28K | $2.66M | Hold |
| Q3 2026 | 216.80K | $1.63M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RGNX and 13F data
RGNX (REGENXBIO INC) is a Health Care company. 29 other funds we track also report a position in RGNX — the largest reported positions include Redmile Group, LLC (US$52.3M), 22NW, LP (US$5.9M), Pale Fire Capital SE (US$5.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RGNX
- Redmile Group, LLC 4.37M sh · $52.34M · Q2 2026
- 22NW, LP 492.76K sh · $5.90M · Q2 2026
- Pale Fire Capital SE 466.21K sh · $5.59M · Q2 2026
More on ArchPoint Investors
FAQ
How long has ArchPoint Investors held RGNX?
ArchPoint Investors has disclosed RGNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ArchPoint Investors's current position in RGNX?
As of Q3 2026, ArchPoint Investors holds 216.80K shares of RGNX (REGENXBIO INC), valued at $1.63M, representing 0.35% of its reported portfolio and ranking #47.
Has ArchPoint Investors been buying or selling RGNX?
In the latest 13F filing (Q3 2026), ArchPoint Investors reduced its position in RGNX. The position peaked in Q1 2024 at 224.28K shares.
Which other funds hold RGNX?
Other major institutional holders of RGNX include Redmile Group, LLC, 22NW, LP, Pale Fire Capital SE, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.